Eutylone
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Eutylone (N-ethylbutylone) is an emerging synthetic stimulant of the cathinone class. It is a structural relative of methylone, with stronger dopamine selectivity and weaker serotonergic character. Eutylone is a dopamine and norepinephrine reuptake inhibitor with partial serotonin-releasing activity, producing its effects by amplifying dopamine reward signaling with mild serotonergic modulation.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylone, mephedrone, MDPV +2 moremethylone, mephedrone, MDPV, cocaine, amphetamine show less
Synthesized in 1967 by Boehringer as part of a broad aryl-aminoketone patent series, eutylone attracted no pharmacological attention for five decades.[2] After the scheduling of N-ethylpentylone in August 2019, eutylone rapidly replaced it in illicit markets as an uncontrolled structural alternative.[3] By 2022–2023, wastewater surveillance ranked it among the top three most prevalent new psychoactive substances globally.[4]
Subjective effects include stimulation, euphoria, increased energy, and mild empathogenic warmth.[5] The experience is more stimulant-forward than MDMA — a buzzing, energized state with modest prosocial warmth that falls short of full entactogenic immersion. Paranoia, agitation, compulsive redosing, and tachycardia are characteristic unsought effects.
Animal data confirm rewarding properties across a wide dose range, and one fatality has been attributed solely to eutylone.[6] The compound is frequently sold as MDMA, meaning users may consume it unknowingly at doses they did not choose — a risk compounded by the absence of any established lethal threshold.[3] The evidence base is exceptionally thin: one foundational pharmacology study, forensic case series, and animal behavioral models constitute nearly all peer-reviewed data.
History[edit]
Discovery
Eutylone was first synthesized in 1967 by Boehringer (later Boehringer Ingelheim) as part of a patent covering aryl-aminoketone derivatives.[2] The compound was one of many analogs claimed in the filing and was never selected for pharmaceutical development. It attracted no pharmacological attention for the following five decades.
Market emergence and global spread
Eutylone first appeared in European drug monitoring systems in 2014,[7][5] but prevalence remained low until 2019. When the US DEA scheduled the related compound N-ethylpentylone in August 2019, forensic laboratories documented a rapid market substitution toward eutylone.[3][8] Within months it became the most commonly identified synthetic cathinone in US forensic seizure data, and by 2022–2023 wastewater surveillance ranked it among the top three most prevalent new psychoactive substances globally.[4][9]
Scheduling
The WHO Expert Committee on Drug Dependence reviewed eutylone at its 44th meeting in October 2021 and recommended placement in Schedule II of the Convention on Psychotropic Substances.[5] International scheduling was formalized in 2022,[10] and most jurisdictions now control eutylone either by name or under generic cathinone provisions.
The compound circulates under the chemical synonyms bk-EBDB, N-ethylbutylone, and β-keto-EBDB.[3] In pharmacology literature it is classified as a third-generation synthetic cathinone — terminology distinguishing it from the initial bath-salt wave (mephedrone, MDPV) and the second-generation N-ethylpentylone period.[11][12] Eutylone's reputation is shaped less by its own identity than by what it pretends to be: it is frequently pressed into tablets and sold as MDMA or mixed into polydrug blends marketed as tusi (pink cocaine),[13] making it one of the most commonly misrepresented substances in current illicit markets.
Chemistry[edit]
Structural class
Eutylone belongs to the methylenedioxy-substituted cathinone subclass — β-keto phenethylamines bearing a 3,4-methylenedioxy ring on the aromatic portion. This places it in the same structural series as methylone (bk-MDMA) and butylone (bk-MBDB). The methylenedioxy ring system is what gives these compounds their partial serotonergic character compared to cathinones without the oxygen bridge.[14]
Eutylone differs from its closest relative methylone by two modifications: an N-ethyl group replacing N-methyl at the nitrogen, and an ethyl chain at the α-carbon replacing hydrogen. These changes increase the molecule's lipophilicity and shift its pharmacological profile away from methylone's MDMA-like serotonergic character toward greater DAT selectivity.[14][7]
Molecular identity
| Molecular formula | C₁₃H₁₇NO₃ |
| Molecular weight | 235.28 g/mol |
The molecule features a 1,3-benzodioxole (methylenedioxy) ring fused to a phenyl ring, a β-keto group at the benzylic position, an ethylamino group at the α-carbon, and an ethyl chain extending from the α-position.[15]
Stereochemistry
Eutylone has two chirality centers, generating four possible stereoisomers. No published studies have examined whether individual stereoisomers differ in pharmacological activity; all characterizations used racemic mixtures.citation needed Class-level evidence from other synthetic cathinones indicates that chirality meaningfully affects potency, but eutylone-specific data represent a gap in the literature.
Physical properties
Eutylone hydrochloride presents as a white crystalline powder with a melting point of approximately 238–239 °C.[2] It is soluble in water, methanol, ethanol, and common organic solvents.[2]
Methylenedioxy cathinones including eutylone resist degradation in biological samples more effectively than non-methylenedioxy analogs.[16] This means blood concentrations measured at laboratory analysis may underestimate actual concentrations at the time of ingestion.
Pharmacology[edit]
Mechanism of action
Eutylone acts as a hybrid transporter compound. It blocks the reuptake of dopamine and norepinephrine — keeping these neurotransmitters active in the synapse longer — while simultaneously causing a partial release of serotonin, achieving roughly half the serotonin output of full releasing agents like MDMA.[1]
Dopamine reuptake inhibitor is eutylone's strongest action, with approximately tenfold selectivity over norepinephrine.[1] This dopamine-dominant profile places eutylone pharmacologically between pure dopamine reuptake inhibitors like cocaine and full mixed monoamine releasers like MDMA. Its serotonergic releasing activity is substantially weaker than methylone's, which more closely approximates the MDMA profile.[1]
Animal behavioral studies confirm this intermediate positioning: eutylone produces subjective effects distinct from both cocaine and MDMA in trained rodents, despite sharing pharmacological targets with both.[17][18]
Pharmacokinetics
No controlled human pharmacokinetic studies have been published for eutylone. No data exist for oral bioavailability, peak blood levels, half-life, or protein binding in humans. All available data derive from forensic casework and laboratory metabolite studies.Forensic blood concentrations span an extremely wide range. In the largest published case series (67 postmortem cases), blood levels ranged from 1.2 to 11,000 ng/mL with a median of 110 ng/mL.[3] A single-substance fatality recorded cardiac blood at 4,290 ng/g.[6] Two non-fatal chemsex exposures showed blood levels of 1,374 and 1,536 ng/mL[10] — overlapping with the lower range of fatal case data.
The primary metabolic pathway is reduction of the β-keto group, with additional processing through N-dealkylation, hydroxylation, demethylenation, and glucuronide conjugation.[3][19] The keto-reduced metabolite and demethylenation products serve as the most reliable urine detection targets.[19] Biliary excretion has been confirmed in an animal liver model — the first such data for any cathinone in this structural series.[20]
No specific liver enzyme studies have been conducted for eutylone. Based on structural analogy to related cathinones, involvement of CYP3A4 and CYP2D6 is expected.inferred
Neuroscience[edit]
Where it acts
Eutylone's primary neural target is the mesolimbic pathway — the brain's core reward circuit running from the ventral tegmental area to the nucleus accumbens.[1] By blocking dopamine reuptake in this circuit, eutylone amplifies reward signaling in the same manner as cocaine. Norepinephrine reuptake blockade adds arousal, cardiovascular activation, and heightened alertness through the brain's noradrenergic arousal systems.
The partial serotonin release distinguishes eutylone's neural signature from pure dopamine blockers. This modest serotonergic component is expected to produce mild prosocial and mood-brightening effects, but whether it engages the deeper empathogenic mechanisms seen with MDMA — such as oxytocin release or fear-response dampening in the amygdala — remains untested.[1]
Why it matters
Eutylone exposure produces a distinctive adaptation pattern in animal models: prior use reduces eutylone's own aversive effects while leaving cocaine and MDMA aversion unaffected.[17] Eutylone history also enhances cocaine reward without enhancing MDMA reward.[18] This selective cross-sensitization suggests eutylone modifies dopaminergic reinforcement circuits specifically rather than producing generalized stimulant tolerance — consistent with the incentive salience model, which predicts that dopamine-dominant compounds drive strong craving while their pleasure ceiling remains constrained.
Whether eutylone produces neuroplastic changes in the brain is unknown — cathinones have not been systematically tested for effects on neural growth pathways, and whether eutylone's partial serotonergic activity engages plasticity mechanisms has not been assessed. The dose-response curve for serotonin-related toxicity is also uncharacterized: the ceiling on serotonin release may reduce risk relative to MDMA, but no data exist.[21] Whether individual stereoisomers differ in dopamine-versus-serotonin selectivity — meaning the racemic mixture's hybrid profile could be an artifact of mixed isomer pharmacology — has not been tested.
Subjective Effects[edit]
Eutylone's experiential character is primarily stimulant — heightened energy, mood elevation, and social disinhibition dominate, while a mild serotonergic warmth adds modest prosocial coloring and tactile sensitivity that remain far less pronounced than with methylone or MDMA.[5] Route of administration and environmental context meaningfully shape the balance between stimulation and warmth. No controlled dosing studies have characterized how the experience shifts across the dose range.
Among synthetic cathinones, eutylone occupies a middle ground between the empathogenic warmth of methylone and the purely dopaminergic push of compounds like dibutylone. Compared to MDMA it is more stimulant-forward and less emotionally immersive; compared to cocaine it offers a warmer affective tone with potentially longer-lasting stimulation.[17][18]
Effect Grid
Clear stimulation with pronounced cognitive euphoria, energy, and sociability enhancement. Disinhibition and communication enhancement are prominent. The partial entactogenic warmth from SERT activity is most apparent at this range — a mild empathy enhancement and tactile euphoria that falls well short of MDMA's emotional immersion but distinguishes eutylone from purely dopaminergic stimulants.
Cardiovascular activation becomes evident: tachycardia, mild body high, and appetite suppression are typical. Bruxism, dry mouth, excessive sweating, and pupil dilation are common. Temperature dysregulation begins. Wakefulness is pronounced, and insomnia is likely for 4–6 hours post-dose.
Compulsive redosing urge may emerge at this tier — eutylone's DAT-dominant profile generates strong craving. Users expecting MDMA-like duration may redose inappropriately due to the shorter, more stimulant-forward character.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch enhancement
Dry mouth · Insomnia · Pupil dilation · Restlessness · Body high · Excessive sweating · Heart rate perception changes · Physical fatigue · Respiratory stimulation · Bodily lightness · Breathing alteration · Dehydration sensation · Muscle tension · Nausea · Bruxism · Dizziness · Headache · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Body high · Excessive sweating · Heart rate perception changes · Physical fatigue · Respiratory stimulation · Bodily lightness · Breathing alteration · Dehydration sensation · Muscle tension · Nausea · Bruxism · Dizziness · Headache · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Motivation enhancement · Aesthetic enhancement · Analysis enhancement · Cognitive impairment · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Openness enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought connectivity · Thought loops · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Delusions of sobriety · Confusion · Thought disorganization
Cognitive impairment · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Thought loops · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Delusions of sobriety · Confusion · Thought disorganization
Empathy enhancement · Irritability · Dysphoria · Emotional lability · Anxiety suppression · Simultaneous emotions
Anxiety suppression · Simultaneous emotions
Communication enhancement · Disinhibition · Emotional susceptibility · Trust enhancement · Flow state · Ego inflation · Derealization
Flow state · Ego inflation · Derealization
Timeline
Initial awareness of mild stimulation and subtle energy increase. Mood may brighten slightly. Effects are easily dismissed as placebo at the lower end of this window.
Rapid escalation of stimulant effects with emerging euphoria and sociability. Heart rate increases noticeably. Mild empathogenic warmth from partial SERT activity may become apparent.
Maximum stimulation, cognitive euphoria, and sociability enhancement. DAT-dominant effects are most pronounced — energy, focus, and disinhibition peak. Appetite suppression and wakefulness are strong.
Gradual decline in stimulation with residual sympathomimetic activation. Euphoria fades while cardiovascular effects (tachycardia, vasoconstriction) may persist. Irritability and restlessness may emerge during this phase.
Post-stimulant residual effects — wakefulness, restlessness, appetite suppression fading, and possible low mood or anhedonia. Physical fatigue may contrast with continued insomnia.
⚠ Avoid driving for at least 6 hours after last dose due to residual sympathomimetic effects, potential fatigue rebound, and cognitive impairment.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- methylone · mephedrone · MDPV
Toxicity
Acute toxicity
No lethal dose has been established for eutylone in any species, and no therapeutic index can be calculated.safety citation needed
One published fatality attributes death solely to eutylone: a 32-year-old man experienced cardiac arrest after several minutes of abnormal behavior following a single use, with a cardiac blood concentration of 4,290 ng/g.[6] Autopsy found no signs of muscle breakdown, suggesting acute heart rhythm disturbance as the mechanism rather than organ failure.[6]
In the largest forensic case series (83 cases across 13 US states), postmortem blood concentrations ranged from 1.2 to 11,000 ng/mL.[3] Most deaths involved multiple substances, complicating attribution. Two non-fatal chemsex exposures demonstrated survival at blood levels (1,374 and 1,536 ng/mL) overlapping with the lower range of fatal case data.[10]
Adulteration hazard
Eutylone is frequently misrepresented as MDMA in illicit markets.[3] It has also been identified in colored powder sold as tusi (pink cocaine) in Miami-Dade fatality cases, typically combined with ketamine, MDMA, and other substances.[13] Standard colorimetric reagent tests cannot distinguish eutylone from MDMA or related compounds; laboratory confirmation is required.[3]
Clinical presentation
The eutylone overdose presentation combines stimulant and serotonergic features[22][5][21][23]:
- Heart and circulation: Rapid heart rate, high blood pressure, heart rhythm disturbances
- Temperature: Dangerous overheating — the primary life-threatening mechanism, especially in hot environments with physical exertion
- Brain and behavior: agitation, confusion, delirium, paranoia, psychosis, hallucinations, seizures
- Serotonin-related: Features of serotonin syndrome possible given partial serotonin-releasing activity
- Muscles and kidneys: Muscle breakdown with potential kidney damage
- Gut: nausea, vomiting
Neurotoxicity
No eutylone-specific neurotoxicity studies exist. Synthetic cathinones as a class can produce brain damage including encephalopathy, seizures, and excited delirium.[21] Methylenedioxy cathinones appear to cause moderate neurotoxicity in animal models — less severe than amphetamine relatives on a per-dose basis — but eutylone-specific thresholds are unknown.[21]
Psychological risks
No controlled studies have assessed eutylone's psychological risk profile. Case reports describe paranoia, delirium, hallucinations, and agitation as acute psychiatric effects.[5]
Animal data reveal a concerning pattern: eutylone's unpleasant effects diminish with repeated use while its rewarding effects persist or strengthen.[17] This selective fading of negative feedback is a risk factor for dose escalation and compulsive use.
The compound's frequent misrepresentation as MDMA creates an additional psychological hazard: users expecting an empathogenic experience encounter a more stimulant-dominant effect, potentially generating confusion, anxiety, or panic.
Tolerance and dependence
Eutylone produces rewarding effects in animal models across a wide dose range (3–32 mg/kg).[11][12] Rewarding and unpleasant effects are dose-dependent and separable, suggesting mediation by partially independent brain mechanisms.[11] The WHO assessment concluded that eutylone's pharmacological profile suggests likelihood of abuse.[5]
Repeated eutylone exposure selectively reduces its own aversive effects without affecting responses to cocaine or MDMA[17] — consistent with tolerance developing to the unpleasant component while reinforcement persists. No human tolerance data, cross-tolerance profiles, or withdrawal characterization exist for eutylone.
Class-level anecdotal reports for synthetic cathinones describe post-use fatigue, depressed mood, anhedonia, and craving, but no systematic study has assessed eutylone-specific withdrawal.
Drug interactions
No published interaction studies exist for eutylone. All risks below are inferred from its pharmacological profile.safety citation needed
Monoamine oxidase inhibitors (MAOIs — phenelzine, tranylcypromine, selegiline, moclobemide) represent the highest-risk combination. Blocked monoamine breakdown combined with eutylone's transporter activity creates risk for serotonin syndrome and dangerous blood pressure spikes.
Serotonergic medications (SSRIs, SNRIs, triptans, tramadol) add to serotonergic load through eutylone's partial serotonin-releasing activity. The ceiling on eutylone's serotonin release may offer some protection compared to full releasers, but this is theoretical.
Stimulants (cocaine, amphetamines, methamphetamine) create additive cardiovascular strain — high blood pressure, rapid heart rate, heart rhythm disturbances, and overheating. Animal data show eutylone history enhances cocaine reward,[18] suggesting effects beyond simple addition.
Depressants (benzodiazepines, opioids, alcohol, GHB) may mask stimulant overdose warning signs. The polydrug pattern documented in forensic fatality series — where stimulant toxicity is obscured by concurrent depressant use — represents a significant hazard.[3][24]
Contraindications
No eutylone-specific contraindication studies exist. The following are inferred from mechanism of action and class-level evidence.safety citation needed
Heart conditions (absolute): Pre-existing heart rhythm disorders, high blood pressure, coronary artery disease, and heart muscle disease. Eutylone's stimulant mechanism directly increases cardiac workload and rhythm disturbance risk. The published fatality involved cardiac arrest.[6]
MAOI therapy (absolute): Risk of serotonin syndrome and dangerously high blood pressure through dual blockade of monoamine breakdown and reuptake/release.
Seizure disorders (absolute): Synthetic cathinones lower the seizure threshold; seizures appear in eutylone's clinical presentation.[5]
Psychotic spectrum disorders (relative): Eutylone-associated paranoia, delirium, and psychosis are documented.[5] Pre-existing vulnerability elevates risk.
Liver impairment (relative): Eutylone is primarily eliminated through the liver; impaired function may prolong exposure and increase toxic metabolite buildup.[20]
Kidney impairment (relative): Muscle breakdown is a documented complication of stimulant cathinone toxicity.[5] Pre-existing kidney compromise increases risk of acute kidney damage.
Hot environments with physical exertion (relative): Heat and activity amplify eutylone's disruption of temperature regulation — the primary life-threatening mechanism in cathinone toxicity.
Pregnancy (absolute): No reproductive toxicity data exist. Stimulant-driven cardiovascular stress poses theoretical risks to fetal development and placental blood flow.safety citation needed
Harm Reduction[edit]
Forms & Identification
Eutylone is one of the most commonly misrepresented substances in current illicit drug markets. Because it shares the methylenedioxy ring system with MDMA, standard Marquis reagent tests produce a similar purple-to-black reaction for both compounds — a positive Marquis result does not confirm MDMA. The only reliable way to confirm eutylone's presence or absence is laboratory-grade analysis such as GC-MS or LC-MS/MS.
When eutylone appears in pressed tablet form, it is virtually indistinguishable from MDMA tablets by appearance alone. Its emergence in polydrug blends like tusi adds further complexity, as these mixtures may contain multiple active substances at unknown ratios.
Guidelines
- Test all substances before use — Marquis alone is insufficient. Multi-reagent testing narrows possibilities, but only laboratory analysis confirms identity.
- Start with the lowest possible dose and wait at least 90 minutes before considering redosing. Eutylone's pharmacokinetics are uncharacterized; onset and peak timing are unpredictable.
- Stay cool. Avoid sustained dancing or heavy exertion in hot environments. Take regular breaks in ventilated areas.
- Hydrate steadily but do not overhydrate — approximately 250 mL (one cup) of water per hour of activity.
- Avoid redosing. Eutylone's reward profile promotes compulsive redosing; the aversive effects that normally signal "enough" fade with repeated use while cardiovascular strain accumulates.
- Have a sober, informed companion present who knows what was taken and can monitor for overheating or behavioral changes.
Set & Setting
Eutylone's stimulant-dominant profile carries specific environmental risks. Hot, crowded environments with sustained physical activity — dance floors, festivals, packed venues — amplify the overheating risk that represents the primary life-threatening mechanism. Cool, ventilated spaces with access to water significantly reduce this danger.
Because eutylone is frequently consumed unknowingly (as misrepresented MDMA), set and setting preparation is often impossible. Users who have tested their substances and confirmed eutylone's presence should choose environments with temperature control, limit physical exertion, and ensure trusted company is present.
Aftercare & integration. The stimulant comedown following eutylone use typically involves fatigue, low mood, and difficulty sleeping. Prioritize sleep — even if it requires a dark, quiet room and patience. Eat nutritious food as appetite returns; stimulant use depletes energy reserves.
Avoid redosing to manage the comedown. The urge to take more to offset fatigue is a predictable consequence of dopamine depletion and not a signal of need. Physical recovery generally takes 24–48 hours; persistent low mood beyond several days warrants professional attention.
Recovery & Support
Eutylone's dopamine-dominant profile and compulsive-redosing potential can lead to patterns of escalating use. If use has become difficult to control, reducing frequency before attempting to stop entirely may ease the transition. Stimulant-specific support resources include SAMHSA's National Helpline (1-800-662-4357), local harm reduction organizations, and peer support communities.
No eutylone-specific withdrawal has been characterized, but class-level reports describe fatigue, depressed mood, and craving after cessation of synthetic cathinone use. Professional support can help manage these symptoms and address underlying patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most eutylone experiences involve manageable stimulation. Seek immediate help if any of the following occur: chest pain or irregular heartbeat, seizure or convulsions, body temperature hot to the touch through clothing, loss of consciousness, severe confusion or inability to communicate, or uncontrollable agitation with violent behavior.
Immediate steps
- Call emergency services immediately if the person is unconscious, seizing, or dangerously overheated.
- Move the person to a cool, quiet area and remove excess clothing.
- Apply cool water to skin — especially neck, armpits, and groin — to lower body temperature.
- Do not restrain the person unless there is immediate danger to themselves or others.
- Do not induce vomiting.
- If the person is unconscious but breathing, place them in the recovery position.
What to tell the dispatcher
State what was taken (or suspected), how much, when, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who seek help for drug-related emergencies — providing honest information can save a life.
Legal Status[edit]
Eutylone's legal status has shifted rapidly since its emergence in illicit markets. First reported to the European Monitoring Centre for Drugs and Drug Addiction in 2014,[7] it was recommended for international scheduling by the WHO Expert Committee on Drug Dependence in October 2021[5] and formally placed in Schedule II of the Convention on Psychotropic Substances in 2022.[10] Most jurisdictions now control eutylone either by specific name or under generic cathinone provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Controlled since March 7, 2014 as a positional isomer of pentylone. Specific listing with dedicated DEA code number established April 10, 2023 (88 FR 21101).[25] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under generic cathinone provisions.citation needed |
| European Union | Monitored since 2014; scheduled 2022 | EMCDDA Early Warning System monitoring since 2014.[7] WHO-recommended Schedule II placement implemented 2022. Individual member state implementation varies. |
| Australia | Controlled substance | Listed by the Australian Office of Drug Control.citation needed |
| New Zealand | Controlled (Misuse of Drugs Act 1975) | Covered by cathinone provisions. Among the highest mass-load NPS detected in NZ wastewater surveillance.[9] |
| International (UN) | Schedule II (Convention on Psychotropic Substances 1971) | WHO ECDD 44th meeting (October 2021) recommendation;[5] scheduling effective 2022.[10] |
references
- [1]
- [2]
- [3]
- [4] ^abNadarajan D et al. (2026) Wastewater analysis as a global toxicovigilance tool for the monitoring of new psychoactive substances — Water Research doi:10.1016/j.watres.2025.124847
- [5]
- [6]